Gastrointestinal Stromal Tumor Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis, Theseus

The Key Gastrointestinal Stromal Tumor Companies in the market include - Blueprint Medicines Corporation, Bayer, Arog Pharmaceuticals, Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others.

DelveInsight's "Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastrointestinal Stromal Tumor Market Forecast [https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report:

*
The Gastrointestinal Stromal Tumor market size was valued approximately ~USD 454 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In 2023, the United States held the largest market share for GIST, accounting for around 69% of the total market size in the 7MM, surpassing other key markets such as the EU4 countries (Germany, Italy, France, and Spain), the United Kingdom, and Japan.

*
In 2023, Germany had the largest market size for GIST among the EU4 and the UK, reaching USD 33 million, while Spain had the smallest market size, around USD 17 million.

*
In 2023, the market size for GIST in Japan was approximately USD 30 million, representing around 7% of the total market across the 7MM.

*
The anticipated introduction of new therapies, including Crenolanib and Bezuclastinib (CGT9486/PLX9486), among others, is expected to significantly impact the GIST market in the coming years.

*
According to DelveInsight's assessment, the total estimated incident cases of GIST in the 7MM were approximately 16,000 in 2023.

*
In 2023, the United States recorded the highest number of incident GIST cases, around 7,000, representing 43% of the total cases in the 7MM. These numbers are anticipated to rise significantly due to advancements in diagnostic and genetic testing.

*
In 2023, the highest number of age-specific incident GIST cases in the 7MM occurred in the 66-80 age group, totaling nearly 6,000 cases, followed by the 51-65 age group with approximately 5,000 cases. The lowest incidence was observed in the 0-17 age group.

*
Among European countries, Germany reported the highest number of GIST incident cases in 2023, with nearly 2,000 cases, followed by Italy with over 1,000 cases. Conversely, Spain had the lowest incident population.

*
In 2023, Japan recorded over 2,500 incident cases of GIST, representing around 16% of the total cases in the 7MM.

*
In 2023, estimates show that within the 7MM, a larger proportion of males (52%) were affected by Gastrointestinal Stromal Tumor (GIST) compared to females (48%).

*
Key Gastrointestinal Stromal Tumor Companies: Blueprint Medicines Corporation, Bayer, Arog Pharmaceuticals, Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others

*
Key Gastrointestinal Stromal Tumor Therapies: Ayvakit (Avapritinib), STIVARGA (Regorafenib), Crenolanib, TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others

*
The Gastrointestinal Stromal Tumor epidemiology based on gender analyzed that males accounted for a larger proportion of about 52% of total incident cases.

*
The Gastrointestinal Stromal Tumor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastrointestinal Stromal Tumor pipeline products will significantly revolutionize the Gastrointestinal Stromal Tumor market dynamics.

Gastrointestinal Stromal Tumor Overview

Gastrointestinal Stromal Tumor (GIST) is a type of soft tissue sarcoma that originates in the gastrointestinal (GI) tract, primarily in the stomach or small intestine. These tumors arise from specialized cells in the GI tract called interstitial cells of Cajal (ICC), which are responsible for regulating muscle contractions in the digestive system.

Get a Free sample for the Gastrointestinal Stromal Tumor Market Report:

https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market [https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastrointestinal Stromal Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastrointestinal Stromal Tumor Epidemiology Segmentation:

The Gastrointestinal Stromal Tumor market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Gastrointestinal Stromal Tumor

*
Prevalent Cases of Gastrointestinal Stromal Tumor by severity

*
Gender-specific Prevalence of Gastrointestinal Stromal Tumor

*
Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Epidemiology Forecast [https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastrointestinal Stromal Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastrointestinal Stromal Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastrointestinal Stromal Tumor Therapies and Key Companies

*
Ayvakit (Avapritinib): Blueprint Medicines Corporation

*
STIVARGA (Regorafenib): Bayer

*
Crenolanib: Arog Pharmaceuticals

*
TAS-116: Taiho Pharmaceutical

*
Bezuclastinib: Cogent Biosciences, Inc./ Plexxikon

*
Iclusig: Ariad Pharmaceuticals

*
Cabozantinib: Exelixis

*
THE-630: Theseus Pharmaceutical

*
Famitinib: Jiangsu Hengrui Medicine

*
PLX9486: Cogent Biosciences

*
Nilotinib: Novartis

*
HQP1351: Ascentage Pharma Group

*
DS 6157: Daiichi Sankyo Company

*
IDRX-42: IDRx, Inc.

Discover more about therapies set to grab major Gastrointestinal Stromal Tumor market share @ Gastrointestinal Stromal Tumor Treatment Market [https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Gastrointestinal Stromal Tumor Market Drivers

*
Rich emerging Gastrointestinal Stromal Tumor pipeline

*
Increasing incidence

*
Understanding of pathophysiology

*
Increased awareness

*
Identification of solid tumor's treatment with NTRK gene fusions

Gastrointestinal Stromal Tumor Market Barriers

*
Resistance against pharmacological therapies

*
Clinical challenges in the management of disease

*
High economic burden

*
Side effects and adverse events after treatment

Scope of the Gastrointestinal Stromal Tumor Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Gastrointestinal Stromal Tumor Companies: Blueprint Medicines Corporation, Bayer, Arog Pharmaceuticals, Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others

*
Key Gastrointestinal Stromal Tumor Therapies: Ayvakit (Avapritinib), STIVARGA (Regorafenib), Crenolanib, TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others

*
Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies

*
Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Gastrointestinal Stromal Tumor Unmet Needs, KOL's views, Analyst's views, Gastrointestinal Stromal Tumor Market Access and Reimbursement

To know more about Gastrointestinal Stromal Tumor companies working in the treatment market, visit @ Gastrointestinal Stromal Tumor Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Gastrointestinal Stromal Tumor Market Report Introduction

2. Executive Summary for Gastrointestinal Stromal Tumor

3. SWOT analysis of Gastrointestinal Stromal Tumor

4. Gastrointestinal Stromal Tumor Patient Share (%) Overview at a Glance

5. Gastrointestinal Stromal Tumor Market Overview at a Glance

6. Gastrointestinal Stromal Tumor Disease Background and Overview

7. Gastrointestinal Stromal Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastrointestinal Stromal Tumor

9. Gastrointestinal Stromal Tumor Current Treatment and Medical Practices

10. Gastrointestinal Stromal Tumor Unmet Needs

11. Gastrointestinal Stromal Tumor Emerging Therapies

12. Gastrointestinal Stromal Tumor Market Outlook

13. Country-Wise Gastrointestinal Stromal Tumor Market Analysis (2020-2034)

14. Gastrointestinal Stromal Tumor Market Access and Reimbursement of Therapies

15. Gastrointestinal Stromal Tumor Market Drivers

16. Gastrointestinal Stromal Tumor Market Barriers

17. Gastrointestinal Stromal Tumor Appendix

18. Gastrointestinal Stromal Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=gastrointestinal-stromal-tumor-market-expected-to-experience-major-growth-by-2032-according-to-delveinsight-novartis-cogent-biosciences-plexxikon-ariad-pharma-exelixis-theseus]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.